Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 826 participants.
Also called NCT07090343
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 826 participants
- Registry
-
NCT07090343
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07090343. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-01 (anticipated); primary completion 2030-09-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement
- Acronym
- REVERSE-TAVR
- Condition
- Aortic Stenosis
- Condition
- Heart Failure
- Intervention (Drug)
- Wegovy ®
- Intervention (Drug)
- Placebo
- Lead sponsor
- Leiden University Medical Center
Record details
- Record id
cardio:ct-nct07090343- Content hash
723a7b9859750533b7e900dd1e814a8f25eb9c86e75e4eb7e3e31b5c60461297